Drug-induced Bleeding

Johnathan W. Hamrick, PharmD; Diane Nykamp, PharmD


US Pharmacist. 2015;40(12):17-21. 

In This Article

Special Consideration for NOAs

For dabigatran, rivaroxaban, and edoxaban, dosages should correspond to the patient's age and renal function.[8] In patients with a history of GI bleeding, apixaban or warfarin should be considered since dabigatran and rivaroxaban may confer a higher risk of bleeding.[9,10] In patients with inflammatory bowel disease or diverticulosis, caution should be exercised with dabigatran and rivaroxaban since these agents are associated with both lower- and upper-GI bleeding.[8] Caution with dabigatran and rivaroxaban also is necessary in patients who are underweight.[8] A common complaint with dabigatran is dyspepsia. This symptom may be perplexing to patients who cannot differentiate between dyspepsia and abdominal pain associated with bleeding.[11]